title: Efficacy of tympanomastoid surgery for control of infection in active chronic otitis media.
abstract: The efficacy of surgery in controlling infection in 272 tympanomastoidectomy procedures for chronic otitis media (COM) was assessed by means of a four-point rating scale that incorporated both symptoms and signs, such as the presence or absence of otorrhea and granulation tissue. Of the 272 procedures, 170 were performed for COM with cholesteatoma and 102 were for active COM with granulation tissue but no cholesteatoma. Forty-seven percent were primary procedures, and 53% were revisions. Minimum follow-up was 12 months for all cases, with a mean of 30 months. Adequate control of infection occurred in 248 (91%) of the 272 cases. Of the 24 cases (9%) that developed persistent infection, 10 were controlled with a combination of oral and topical antibiotics and/or delayed skin grafting in the office. Thus overall satisfactory control of infection was achieved in 258 of 272 cases (95%). The outcome was influenced by the diagnostic category of COM: COM with cholesteatoma did significantly better than COM with granulation tissue (P = 0.02). The outcome was not influenced by the following variables: primary versus revision surgery, canal wall-up versus canal wall-down surgery, and extent of disease. The results suggest that active COM with granulation tissue may be more difficult to control than COM with cholesteatoma.
authors.affiliation: Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston 02114, USA.
authors.forename: S N
authors.initials: SN
authors.lastname: Merchant
authors.forename: P
authors.initials: P
authors.lastname: Wang
authors.forename: C H
authors.initials: CH
authors.lastname: Jang
authors.forename: R J
authors.initials: RJ
authors.lastname: Glynn
authors.forename: S D
authors.initials: SD
authors.lastname: Rauch
authors.forename: M J
authors.initials: MJ
authors.lastname: McKenna
authors.forename: J B
authors.initials: JB
authors.lastname: Nadol
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018424:Cholesteatoma, Middle Ear / Q000473:pathology / Q000517:prevention & control / Q000601:surgery; D002908:Chronic Disease; D004424:Ear Canal / Q000601:surgery; D004432:Ear, Middle / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006097:Granulation Tissue / Q000473:pathology; D006801:Humans; D008297:Male; D008416:Mastoid / Q000601:surgery*; D010035:Otitis Media, Suppurative / Q000473:pathology / Q000517:prevention & control / Q000601:surgery*; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D016038:Skin Transplantation; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents